# Auron Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/auron-therapeutics

- Industry: Biotechnology
- Headquarters: Newton, US
- Website: www.aurontx.com
- Total disclosed funding: $52M
- Latest round: Series B (Dec 18, 2024)
- Investors on record: 12

## About

Founded in 2018 and based in Massachusetts, US, Auron Therapeutics, Inc. operates as a developer of therapeutic medicine that could help cure individuals with cancer whether it's solid or hematological tumors. In December 2024, Auron Therapeutics, Inc. raised USD 13.3 million in series B funding led by returning investor Data Collective, with participation from other returning investors Apollo Health Ventures, Arkin Holdings, BrightEdge Ventures, Casdin Capital, Mubadala Capital, Polaris Partners, and Qiming Venture Partners. An individual and other unspecified investors also participated in the round. The round was part of a larger USD 41.7 equity funding.

The company aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to the transformation of malignant cells into more normal functioning cells.

## Funding rounds

- Series B, Dec 18, 2024, $13M — Polaris Partners, Qiming Venture Partners, Casdin Capital, DCVC, Arkin Capital, Mubadala Capital, Apollo Health Ventures, BrightEdge Ventures
- Series A, Jul 14, 2022, $26M — Polaris Partners, Qiming Venture Partners, Casdin Capital, Eli Lilly & Company, DCVC, Arkin Capital, Mubadala Capital, Apollo Health Ventures, Breeze Bio, Inc., BrightEdge Ventures, Totus Medicines Inc., Creyon Bio, Inc.
- Seed, Jan 27, 2021, $13M — Polaris Partners, Qiming Venture Partners, Casdin Capital, Eli Lilly & Company, Arkin Capital, BrightEdge Ventures

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series A, Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Seed, Series A, Series B
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Seed, Series A, Series B
- Eli Lilly & Company — Seed, Series A
- Arkin Capital (https://capitalatlas.ai/funds/arkin-capital) — Seed, Series A, Series B
- BrightEdge Ventures (https://capitalatlas.ai/funds/brightedge-ventures) — Seed, Series A, Series B
- DCVC (https://capitalatlas.ai/funds/dcvc) — Series A, Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A, Series B
- Apollo Health Ventures (https://capitalatlas.ai/funds/apollo-health-ventures) — Series A, Series B
- Breeze Bio, Inc. — Series A
- Totus Medicines Inc. — Series A
- Creyon Bio, Inc. — Series A